구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
BCMA ADC (belantamab mafodotin). r/r MM. ocular tox·CRS. Darzalex·CAR-T·GPRC5D ADC와 후선 포지셔닝.
BCMA-directed ADC (belantamab mafodotin / MMAF); accelerated approval then US withdrawal after confirmatory trial miss; ocular toxicity hallmark.
기전. Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
BCMA
Multiple myeloma
US (withdrawn), EU conditional
Discontinued
blenrep · belantamab mafodotin · Blenrep · GSK2857916
2026-09-10
Data Confidence · High
Development Signal · Established
ADC
MMAF
Non-cleavable
humanized anti-B-cell maturation antigen (BCMA) monoclonal antibody conjugated to monomethyl auristatin F (MM
BCMA-targeted ADC with ocular AEs
구조화 데이터
BCMA-targeted ADC with ocular AEs
bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs)
MMAF
Non-cleavable
BCMA · BCMA expression on myeloma cells.
Ocular toxicity monitoring
Relapsed/refractory MM
Ocular toxicity monitoring
Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death.
cytokine release syndrome, all grade 1
MMAF (auristatin F) disrupts microtubules; non-cleavable linker.
BCMA expression on myeloma cells.
bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs)
구조화 데이터
CDX model
cynomolgus, monkeys
16.8
M-protein; corneal microcysts on ophthalmic exam
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval
APPROVAL · 2020년 8월
US withdrawal after confirmatory trial
DISCONTINUED · 2022년 11월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
BCMA ADC (belantamab mafodotin). r/r MM. ocular tox·CRS. Darzalex·CAR-T·GPRC5D ADC와 후선 포지셔닝.
BCMA-directed ADC (belantamab mafodotin / MMAF); accelerated approval then US withdrawal after confirmatory trial miss; ocular toxicity hallmark.
기전. Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
BCMA
Multiple myeloma
US (withdrawn), EU conditional
Discontinued
blenrep · belantamab mafodotin · Blenrep · GSK2857916
2026-09-10
Data Confidence · High
Development Signal · Established
ADC
MMAF
Non-cleavable
humanized anti-B-cell maturation antigen (BCMA) monoclonal antibody conjugated to monomethyl auristatin F (MM
BCMA-targeted ADC with ocular AEs
구조화 데이터
BCMA-targeted ADC with ocular AEs
bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs)
MMAF
Non-cleavable
BCMA · BCMA expression on myeloma cells.
Ocular toxicity monitoring
Relapsed/refractory MM
Ocular toxicity monitoring
Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death.
cytokine release syndrome, all grade 1
MMAF (auristatin F) disrupts microtubules; non-cleavable linker.
BCMA expression on myeloma cells.
bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs)
구조화 데이터
CDX model
cynomolgus, monkeys
16.8
M-protein; corneal microcysts on ophthalmic exam
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval
APPROVAL · 2020년 8월
US withdrawal after confirmatory trial
DISCONTINUED · 2022년 11월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.